Please assess the completion status of the following clinical trial:

Trial Title: Long-Duration Stimulant Treatment Study of ADHD in Young Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Parents/guardians and children must speak English and/or Spanish; parents/guardians must sign consent form; children must verbally assent.~2. Boys and girls from 4-5 years old (inclusive) at screening.~3. Children who meet the DSM-IV criteria for a primary diagnosis of ADHD (combined or hyperactive subtype), with symptoms present for at least 9 months.~4. Children who demonstrate adequate need for treatment due to ADHD symptom-severity and clinical impairment.~5. Children with IQ of at least 70 confirmed by valid IQ test.~6. Children who are in educational settings (pre-school, kindergarten, or elementary school program) with at least 8 same-age peers for at least two half days weekly.~7. Parents and children who can attend weekly study visits.~8. Children who are naïve to ADHD medications; received ADHD medications in the past but are not currently treated; or on ADHD medications but finding them inconvenient (due to short duration of action) or not very helpful~Exclusion Criteria:~1. Children and parents/guardians who do not understand or cannot follow necessary instructions; children and parents who are unwilling to comply with study procedures or cooperate with child psychiatrist.~2. Children taking excluded medications.~3. Children with history of intolerance to MPH/stimulant medications or no response to adequate stimulant trials.~4. Children with current adjustment disorder, autism, psychosis, bipolar disorder, significant suicidality, or other psychiatric disorders.~5. Children with history of physical, sexual, or emotional abuse, which lead to a significant impact on the clinical presentation and potentially some ADHD symptoms.~6. Children with screening abnormalities deemed clinically significant by child psychiatrist.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- ADHD Treatment Group (Type: EXPERIMENTAL): Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD.

Based on this trial design, predict the completion outcome and termination type (if applicable).